Funding was co-led by B Capital and U.S. Venture Partners, according to a news release. The money will support development of personalized cervical spinal fusion implants and commercialization of aprevo lumbar fusion devices.
Aprevo has FDA breakthrough device designation for lumbar and cervical patient-specific interbody fusion devices. Carlsmed’s aprevo cervical fusion implant is expected to launch in 2025.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
